These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3142496)

  • 1. [Incidence of inhibitors in children with hemophilia A].
    Izquierdo-Ramírez J; Contreras-Mulato EL; Sotelo-Ham EI; Marín-Palomares T; Dueñas-González MT; Benítez-Aranda H
    Bol Med Hosp Infant Mex; 1988 Sep; 45(9):578-82. PubMed ID: 3142496
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquired circulating anticoagulants in hemophilia A.
    Strauss HS
    N Engl J Med; 1969 Oct; 281(16):866-73. PubMed ID: 5812255
    [No Abstract]   [Full Text] [Related]  

  • 3. Incidence and course of inhibitors among patients with classic hemophilia.
    Kasper CK
    Thromb Diath Haemorrh; 1973 Nov; 30(2):263-71. PubMed ID: 4773365
    [No Abstract]   [Full Text] [Related]  

  • 4. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
    Guérois C; Laurian Y; Rothschild C; Parquet-Gernez A; Duclos AM; Négrier C; Vicariot M; Fimbel B; Fressinaud E; Fiks-Sigaud M
    Thromb Haemost; 1995 Feb; 73(2):215-8. PubMed ID: 7792732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Autocorrection of coagulation time in Hemophilia A].
    Schneer JH; Chipail A; Mănăila T
    Rev Med Chir Soc Med Nat Iasi; 1975; 79(2):211-4. PubMed ID: 1166156
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.
    Orsini F; Rotschild C; Beurrier P; Faradji A; Goudemand J; Polack B
    Haematologica; 2005 Sep; 90(9):1288-90. PubMed ID: 16154861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Determination of factor VIII inhibitor in hemophiliacs].
    Mancini AF; Rosito P; Paolucci G
    Minerva Pediatr; 1976 Nov; 28(36):2181-5. PubMed ID: 995099
    [No Abstract]   [Full Text] [Related]  

  • 9. [Circulating anticoagulants in hemophilia A].
    Michalski R; Lopaciuk S
    Acta Haematol Pol; 1973; 4(3):203-9. PubMed ID: 4800573
    [No Abstract]   [Full Text] [Related]  

  • 10. [Transient inhibitors developed in two cases of hemophilia A].
    Fujiwara F; Kanoh G; Ogawa H; Takaya K; Hibi S; Shima M; Yoshioka A; Imashuku S
    Rinsho Ketsueki; 1997 Dec; 38(12):1263-8. PubMed ID: 9455145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of factor VIII and IX inhibitors with ABO blood groups in 150 patients with haemophilia A and B.
    Torghabeh HM; Pourfathollah A; Shooshtari MM; Yazdi ZR
    Iran J Allergy Asthma Immunol; 2006 Mar; 5(1):33-4. PubMed ID: 17242502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ["Inhibitory" form of hemophilia in children].
    Mazurin AV; Iakunina LN; Plakhuta TG
    Probl Gematol Pereliv Krovi; 1978 Jul; (7):18-21. PubMed ID: 674137
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A.
    Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J
    Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of hemophilia complicated by inhibitors.
    Scand J Haematol Suppl; 1980; 35():135-64. PubMed ID: 6770458
    [No Abstract]   [Full Text] [Related]  

  • 16. Mortality in hemophiliac populations.
    Weighton W
    Trans Assoc Life Insur Med Dir Am; 1984; 66():120-32. PubMed ID: 6442479
    [No Abstract]   [Full Text] [Related]  

  • 17. Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. A study of the cooperative group of hemophilia.
    Ambriz-Fernández R; Reyna-Fregoso MP; Pizzuto-Chávez J; Rodríguez-Moyado H; Farfán-Canto JM; Trueba-Christy E; Collazo-Jaloma J
    Arch Invest Med (Mex); 1985; 16(3):225-35. PubMed ID: 3938639
    [No Abstract]   [Full Text] [Related]  

  • 18. Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required.
    Calvez T; Laurian Y
    Br J Haematol; 2006 Mar; 132(6):798-800; author reply 800-1. PubMed ID: 16487187
    [No Abstract]   [Full Text] [Related]  

  • 19. The natural history of factor VIII inhibitors in patients with hemophilia A.
    Gill FM
    Prog Clin Biol Res; 1984; 150():19-29. PubMed ID: 6431427
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantitative effects of the reaction between factor VIII and factor VIII inhibitors.
    McMillan CW; Elston RC
    Thromb Diath Haemorrh; 1971 Aug; 26(1):124-34. PubMed ID: 5112370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.